21 results

e1 Coalition Forces of Immunologists and Oncologists for Defeating Cancer
Eui-Cheol Shin
KMSID: 1142982   Immune Netw. 2020;20(1):e1.  Published online 2020 February 20    DOI: http://dx.doi.org/10.4110/in.2020.20.e1
         
e2 Re-defining T-Cell Exhaustion: Subset, Function, and Regulation
Se Jin Im, Sang-Jun Ha
KMSID: 1142985   Immune Netw. 2020;20(1):e2.  Published online 2020 February 4    DOI: http://dx.doi.org/10.4110/in.2020.20.e2
         
e3 Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy
Seongju Jeong, Su-Hyung Park
KMSID: 1142986   Immune Netw. 2020;20(1):e3.  Published online 2020 February 4    DOI: http://dx.doi.org/10.4110/in.2020.20.e3
         
e4 Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy
Jung-Ho Kim, Beom Seok Kim, Sang-Kyou Lee
KMSID: 1142987   Immune Netw. 2020;20(1):e4.  Published online 2020 February 4    DOI: http://dx.doi.org/10.4110/in.2020.20.e4
         
e5 Heterogeneity of Human γδ T Cells and Their Role in Cancer Immunity
Hye Won Lee, Yun Shin Chung, Tae Jin Kim
KMSID: 1142988   Immune Netw. 2020;20(1):e5.  Published online 2020 February 4    DOI: http://dx.doi.org/10.4110/in.2020.20.e5
         
e6 IL-17-Producing Cells in Tumor Immunity: Friends or Foes?
Da-Sol Kuen, Byung-Seok Kim, Yeonseok Chung
KMSID: 1142989   Immune Netw. 2020;20(1):e6.  Published online 2020 February 4    DOI: http://dx.doi.org/10.4110/in.2020.20.e6
         
e7 Far Beyond Cancer Immunotherapy: Reversion of Multi-Malignant Phenotypes of Immunotherapeutic-Resistant Cancer by Targeting the NANOG Signaling Axis
Se Jin Oh, Jaeyoon Lee, Yukang Kim, Kwon-Ho Song, Eunho Cho, Minsung Kim, Tae Woo Kim, Heejae Jung
KMSID: 1142990   Immune Netw. 2020;20(1):e7.  Published online 2020 February 4    DOI: http://dx.doi.org/10.4110/in.2020.20.e7
         
e8 Peripheral Blood Immune Cell-based Biomarkers in Anti-PD-1/PD-L1 Therapy
Kyung Hwan Kim, Chang Gon Kim, Eui-Cheol Shin
KMSID: 1142991   Immune Netw. 2020;20(1):e8.  Published online 2020 February 4    DOI: http://dx.doi.org/10.4110/in.2020.20.e8
         
e9 Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors
Juwhan Choi, Sung Yong Lee
KMSID: 1142992   Immune Netw. 2020;20(1):e9.  Published online 2020 February 4    DOI: http://dx.doi.org/10.4110/in.2020.20.e9
         
e10 Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives
Sun Min Lim, Min Hee Hong, Hye Ryun Kim
KMSID: 1142983   Immune Netw. 2020;20(1):e10.  Published online 2020 February 4    DOI: http://dx.doi.org/10.4110/in.2020.20.e10
         
e11 Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?
Hye Won Lee, Kyung Joo Cho, Jun Yong Park
KMSID: 1142984   Immune Netw. 2020;20(1):e11.  Published online 2020 February 4    DOI: http://dx.doi.org/10.4110/in.2020.20.e11
         
e2 Re-defining T-Cell Exhaustion: Subset, Function, and Regulation
Se Jin Im, Sang-Jun Ha
KMSID: 1148272   Immune Netw. 2020;20(1):e2.  Published online 2020 February 20    DOI: http://dx.doi.org/10.4110/in.2020.20.e2
         
e3 Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy
Seongju Jeong, Su-Hyung Park
KMSID: 1148275   Immune Netw. 2020;20(1):e3.  Published online 2020 February 7    DOI: http://dx.doi.org/10.4110/in.2020.20.e3
         
e4 Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy
Jung-Ho Kim, Beom Seok Kim, Sang-Kyou Lee
KMSID: 1148276   Immune Netw. 2020;20(1):e4.  Published online 2020 February 11    DOI: http://dx.doi.org/10.4110/in.2020.20.e4
         
e5 Heterogeneity of Human γδ T Cells and Their Role in Cancer Immunity
Hye Won Lee, Yun Shin Chung, Tae Jin Kim
KMSID: 1148277   Immune Netw. 2020;20(1):e5.  Published online 2020 February 14    DOI: http://dx.doi.org/10.4110/in.2020.20.e5
         
e6 IL-17-Producing Cells in Tumor Immunity: Friends or Foes?
Da-Sol Kuen, Byung-Seok Kim, Yeonseok Chung
KMSID: 1148278   Immune Netw. 2020;20(1):e6.  Published online 2020 February 7    DOI: http://dx.doi.org/10.4110/in.2020.20.e6
         
e7 Far Beyond Cancer Immunotherapy: Reversion of Multi-Malignant Phenotypes of Immunotherapeutic-Resistant Cancer by Targeting the NANOG Signaling Axis
Se Jin Oh, Jaeyoon Lee, Yukang Kim, Kwon-Ho Song, Eunho Cho, Minsung Kim, Heejae Jung, Tae Woo Kim
KMSID: 1148279   Immune Netw. 2020;20(1):e7.  Published online 2020 January 20    DOI: http://dx.doi.org/10.4110/in.2020.20.e7
         
e8 Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy
Kyung Hwan Kim, Chang Gon Kim, Eui-Cheol Shin
KMSID: 1148280   Immune Netw. 2020;20(1):e8.  Published online 2020 February 10    DOI: http://dx.doi.org/10.4110/in.2020.20.e8
         
e9 Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors
Juwhan Choi, Sung Yong Lee
KMSID: 1148281   Immune Netw. 2020;20(1):e9.  Published online 2020 February 17    DOI: http://dx.doi.org/10.4110/in.2020.20.e9
         
e10 Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives
Sun Min Lim, Min Hee Hong, Hye Ryun Kim
KMSID: 1148273   Immune Netw. 2020;20(1):e10.  Published online 2020 January 27    DOI: http://dx.doi.org/10.4110/in.2020.20.e10
         
e11 Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?
Hye Won Lee, Kyung Joo Cho, Jun Yong Park
KMSID: 1148274   Immune Netw. 2020;20(1):e11.  Published online 2020 February 17    DOI: http://dx.doi.org/10.4110/in.2020.20.e11
         
Articles from Immune Network are provided here courtesy of The Korean Association of Immunobiologists